Hemolytic anemia during 24 weeks of ribavirin and interferon-α2b combination therapy does not influence the cardiac function of patients with viral hepatitis C

被引：0

作者：

Sato, S ^{[1
]}

Furuta, K

Miyake, T

Mishiro, T

Kohge, N

Akagi, S

Uchida, Y

Rumi, MAK

Ishihara, S

Adachi, K

Kinoshita, Y

机构：

[1] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, Matsue, Shimane, Japan

[2] Shimane Univ Hosp, Div Gastrointestinal Endoscopy, Matsue, Shimane, Japan

来源：

JOURNAL OF CLINICAL GASTROENTEROLOGY | 2006年 / 40卷 / 01期

关键词：

D O I：

10.1097/01.mcg.0000190781.96021.20

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：88 / 89

页数：2

共 50 条

[21] Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks
Wada, Yuki
Tamai, Hideyuki
Uno, Akiko
Kawashima, Akira
Shingaki, Naoki
Mori, Yoshiyuki
Moribata, Kosaku
Miyata, Kaori
Higashi, Katsuhiko
Deguchi, Hisanobu
Ueda, Kazuki
Inoue, Izumi
Maekita, Takao
Iguchi, Mikitaka
Kato, Jun
Ichinose, Masao
HEPATOLOGY RESEARCH, 2014, 44 (02) : 179 - 186
[22] Effects of ribavirin combined with interferon-α2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads
Enomoto, M
Nishiguchi, S
Kohmoto, M
Tamori, A
Habu, D
Takeda, T
Seki, S
Shiomi, S
JOURNAL OF VIRAL HEPATITIS, 2004, 11 (05) : 448 - 454
[23] Therapy of acute hepatitis C with interferon-α2b plus ribavirin in a health care worker
Ertem, GT
Tulek, N
Oral, B
Kinikli, S
ACTA GASTRO-ENTEROLOGICA BELGICA, 2005, 68 (01) : 104 - 106
[24] Efficacy of hepatitis B vaccination and interferon-α-2b combination therapy versus interferon-α-2b monotherapy in children with chronic hepatitis B
Helvaci, M
Kizilgunesler, A
Kasirga, E
Ozbal, E
Kuzu, M
Sozen, G
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (07) : 785 - 791
[25] A prospective study of neuropsychiatric symptoms associated with interferon-α-2b and ribavirin therapy for patients with chronic hepatitis C
Dieperink, E
Ho, SB
Thuras, P
Willenbring, ML
PSYCHOSOMATICS, 2003, 44 (02) : 104 - 112
[26] Meta-analysis:: combination therapy with interferon-α 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon
Miguel, RS
Guillén, F
Cabasés, JM
Buti, M
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (09) : 1611 - 1621
[27] Investigation of hyperuricemia during pegylated-interferon-α2b plus ribavirin combination therapy in patients with chronic hepatitis C
Yamashita, Naoki
Enjoji, Munechika
Kotoh, Kazuhiro
Kato, Masaki
Ueda, Akihiro
Horikawa, Yuki
Tajiri, Hirotaka
Higuchi, Nobito
Kinukawa, Naoko
Nakamuta, Makoto
Takayanagi, Ryoichi
JOURNAL OF DIGESTIVE DISEASES, 2008, 9 (01) : 27 - 31
[28] Interferon-α-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone:: An Italian multicenter, randomized, controlled, clinical study
Barbaro, G
Di Lorenzo, G
Soldini, M
Giancaspro, G
Bellomo, G
Belloni, G
Grisorio, B
Annese, M
Bacca, D
Francavilla, R
Rizzo, G
Barbarini, G
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (12): : 2445 - 2451
[29] Ribavirin and interferon-α-2b combination treatment of chronic hepatitis C in patients with haemophilia and other clotting disorders.
Fried, R
Meili, E
Peter, K
Hartmann, S
Tsakiris, D
Fried, C
Egger, H
Zanni, M
Marbet, G
GASTROENTEROLOGY, 1999, 116 (04) : A1212 - A1212
[30] Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-α combination therapy and interferon-α monotherapy of patients with chronic hepatitis C
Hoffmann, RM
Berg, T
Teuber, G
Prümmer, O
Leifeld, L
Jung, MC
Spengler, U
Zeuzem, S
Hopf, U
Pape, GR
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1999, 37 (08): : 715 - 723

← 1 2 3 4 5 →